Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens

Parkinsonism and Related Disorders

Volumn 20, Issue 1, 2014, Pages 27-31

  Mancini, F ^a   Comi, C ^b   Oggioni, G D ^b   Pacchetti, C ^c   Calandrella, D ^a   Coletti Moja, M ^d   Riboldazzi, G ^e   Tunesi, S ^b   Dal Fante, M ^f   Manfredi, L ^a   Lacerenza, M ^a   Cantello, R ^b   Antonini, A ^g  

^a Fondazione Opera San Camillo   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f Clinic San Pio X   (Italy)

^g IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Levodopa intestinal infusion; Neuropathy; Parkinson's disease

Indexed keywords

CYANOCOBALAMIN; DOPAMINE RECEPTOR STIMULATING AGENT; HOMOCYSTEINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

AGED; ARTICLE; BIOCHEMISTRY; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION;

LEVODOPA INTESTINAL INFUSION; NEUROPATHY; PARKINSON'S DISEASE;

AGED; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; ELECTROMYOGRAPHY; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; VITAMIN B 12;

EID: 84892825675     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.09.007     Document Type: Article

References (21)

1. Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A., et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010, 68:28-36.
2. Rajabally Y.A., Martey J. Neuropathy in Parkinson's Disease. Prevalence and determinants. Neurology 2011, 77:1947-1950.
3. Antonini A., Isaias I.U., Canesi M., Zibetti M., Mancini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007, 22:1145-1149.
4. Manca D., Cossu G., Murgia D., Molari A., Ferrigno P., Marcia E., et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009, 24:2293-2294.
5. Urban P.P., Wellach I., Faiss S., Layer P., Rosenkranz T., Knop K., et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010, 25:1748-1752.
6. Klostermann F., Jugel C., Müller T., Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. JNeural Transm 2012, 119:369-372.
7. Santos-García D., de la Fuente-Fernández R., Valldeoriola F., Palasí A., Carrillo F., Grande M., et al. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. JNeurol 2012, 259:1668-1672.
8. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatr 1992, 55:181-184.
9. Miller R.G., Asbury A.K., Carter T. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005, 64:199-207.
10. Meulstee J., van der Meche F.G.A. Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barre syndrome. JNeurol Neurosurg Psychiatr 1995, 59:482-486. the Dutch Guillain-Barre Study Group.
11. Protection of patients' rights to privacy. BMJ 1995, 311:1272. International Committee of Medical Journal Editors.
12. Abraham N.S. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012, 28:615-620.
13. Postuma R.B., Lang A.E. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?. Neurology 2004, 63:886-891.
14. Puri V., Chaudhry N., Goel S., Gulati P., Nehru R., Chowdhury D. Vitamin B12 deficiency: a clinical and electrophysiological profile. Electromyogr Clin Neurophysiol 2005, 45:273-284.
15. Sakly G., Hellara O., Trabelsi A., Dogui M. Reversible peripheral neuropathy induced by vitamin B12 deficiency. Neurophysiol Clin 2005, 35:149-153.
16. Westin J., Nyholm D., Pålhagen S., Willows T., Groth T., Dougherty M., et al. Apharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol 2011, 34:61-65.
17. Muller T., Renger K., Khun W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004, 61:657-660.
18. Scalabrino G. The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: lessons learned from its deficiency. Prog Neurobiol 2009, 88:203-220.
19. Smith A.R., Macfarlane G.T., Reynolds N., O'May G.A., Bahrami B., Macfarlane S. Effect of a synbiotic on microbial community structure in a continuous culture model of the gastric microbiota in enteral nutrition patients. FEMS Microbiol Ecol 2012, 80:135-145.
20. Zhang L., Li N., des Robert C., Fang M., Liboni K., McMahon R., et al. Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model. JPediatr Gastroenterol Nutr 2006, 42:545-552.
21. Nolano M., Provitera V., Estraneo A., Selim M.M., Caporaso G., Stancanelli A., et al. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain 2008 Jul, 131(Pt 7):1903-1911.